STOCK TITAN
The best stock market news and trading tools all in one place—your must-have platform for investing success.
A must-have platform for stock market information, offering the best tools and updates to supercharge your trading.
Your trusted source for the best stock market news, trading tools, and expert advice. Everything traders need, in one place.

CENTOGENE and the Laboratory of Human Genetics of Infectious Diseases at Institut Imagine Announce Rare Disease Research Collaboration

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Positive)
Tags
Rhea-AI Summary
CENTOGENE N.V. (CNTG) and the Laboratory of Human Genetics of Infectious Diseases at Institut Imagine have announced a strategic research collaboration to accelerate and de-risk drug discovery and clinical development for rare disease patients. The collaboration aims to leverage the CENTOGENE Biodatabank, containing over 70 million unique genetic variants collected from more than 800,000 patients from over 120 countries, to discover and validate novel genetic and biochemical targets for future development of rare disease therapies. The partnership will integrate multiomics and bioinformatics to analyze the diverse data and improve patient health outcomes.
Positive
  • None.
Negative
  • None.

Insights

The strategic collaboration between CENTOGENE and the Laboratory of Human Genetics of Infectious Diseases represents a significant step in the field of rare and neurodegenerative disease research. The integration of multiomics and bioinformatics to analyze the CENTOGENE Biodatabank's extensive genetic variant data could lead to the discovery of novel therapeutic targets. This approach is crucial because the traditional drug development process for rare diseases is often hampered by small patient populations and a lack of comprehensive disease understanding. By identifying and validating new genetic and biochemical targets, the collaboration aims to expedite the drug discovery process, which could result in faster and more efficient clinical trials.

For stakeholders, this collaboration holds the potential for reducing the time and cost associated with bringing new rare disease therapies to market. The focus on de-risking drug development is particularly important given the high failure rates and substantial investments required in the pharmaceutical industry. In the long-term, successful identification of actionable targets could lead to an increase in the treatment options available to rare disease patients, addressing a significant area of unmet medical need.

The use of the CENTOGENE Biodatabank, which includes data from a diverse patient population spanning over 120 countries, is a strategic asset in understanding the genetic underpinnings of rare diseases. The application of multiomic technologies, which include genomics, transcriptomics, proteomics and metabolomics, provides a holistic view of the biological processes involved in disease manifestation. This comprehensive approach is essential for pinpointing precise genetic factors that could be targeted by new drugs.

The collaboration's emphasis on multiethnic insights is particularly noteworthy, as it acknowledges the importance of genetic diversity in disease research. This diversity can lead to the discovery of genetic markers that are specific to certain populations, which may be missed in less diverse datasets. The potential benefits of this research extend beyond the development of new therapies; it could also improve diagnostic accuracy and enable personalized treatment strategies that are tailored to an individual's genetic makeup.

From an economic standpoint, the partnership between CENTOGENE and the Laboratory of Human Genetics of Infectious Diseases could have a profound impact on the healthcare market, particularly in the niche of rare diseases. The cost of developing new drugs is often justified by the potential for significant returns on investment, but this is less certain in the rare disease market due to smaller patient populations. By leveraging the CENTOGENE Biodatabank to de-risk the drug discovery process, the collaboration may lead to more sustainable economic models for rare disease therapy development.

Furthermore, improved health outcomes for rare disease patients could translate into reduced long-term healthcare costs, as effective treatments can decrease the need for extensive medical care and hospitalizations. This aspect is of particular interest to healthcare payers and policymakers who are focused on cost containment while improving patient care. The collaboration's potential to deliver targeted and effective therapies could serve as a model for future research and development efforts in the healthcare industry.

Aims to Leverage Diversified Data to Accelerate and De-Risk Drug Discovery and Clinical Development

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Jan. 25, 2024 (GLOBE NEWSWIRE) -- CENTOGENE N.V. (Nasdaq: CNTG) (the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, and the Laboratory of Human Genetics of Infectious Diseases (the “Lab”) at Institut Imagine today announced a strategic research collaboration to improve health outcomes for rare disease patients by accelerating and de-risking drug discovery and clinical development.

As part of the collaboration, CENTOGENE and the Lab will leverage the CENTOGENE Biodatabank, which contains over 70 million unique genetic variants collected from more than 800,000 patients from over 120 countries – providing valuable and unparalleled insights into the role that specific genes play in disease. Together, CENTOGENE and the Lab will jointly agree on future research projects that will integrate multiomics and bioinformatics to analyze this highly diverse data to discover and validate novel genetic and biochemical targets that can be used for future development of rare disease therapies. By proving and validating the relevance of a target to disease and that modulating it will have the desired outcome, drug discovery and development can be significantly accelerated and de-risked. Specific targets of the collaboration have not been disclosed.

“Our mission is to gain a better understanding of the human genetic and immunological determinants of rare and common infectious diseases,” said Dr. Jean-Laurent Casanova, Head of the Laboratory of Human Genetics of Infectious Diseases. “By working together with CENTOGENE to leverage deep multiomic and multiethnic insights, we will be able to accelerate more precise treatment options and ultimately improve patient health outcomes.”

“At CENTOGENE, we are committed to delivering data-driven, life-changing answers to accelerate and de-risk drug discovery, development, and commercialization. By leveraging our highly diverse insights, multiomic technologies, and rare disease expertise, we are able to qualitatively make a difference in the success of research and early clinical development,” said Prof. Peter Bauer, CENTOGENE’s Chief Medical and Genomic Officer. “In teaming up with the Laboratory of Human Genetics of Infectious Diseases at Institut Imagine, we will be able to collaboratively contribute to some of the world’s leading research projects to transform data into life-saving therapeutics for patients around the world.”

With more than 350 million people worldwide affected by over 7,000 rare diseases, approximately 95% of which do not have an available treatment, rare disease patients are facing some of the highest unmet medical needs. Progress towards the development of new therapies and cures in rare diseases is hindered by several factors:

  • A lack of disease understanding compounded by small patient population
  • Difficulties in correctly diagnosing and identifying patients for trials
  • A lack of clearly defined clinical endpoints
  • Complexities around leveraging real-world data

By combining expertise, the collaboration will support end-to-end, data-driven drug discovery and clinical development to enable better health outcomes for rare disease patients.

“Since its creation in 2007, Institut Imagine has been forming partnerships with the leading healthcare players to combine resources and transform care for patients around the world,” said Stanislas Lyonnet, Director of Institut Imagine. “Institut Imagine is excited to see this partnership between the Laboratory of Human Genetics of Infectious Diseases and CENTOGENE to advance research and make an impact for patients for years to come.”

Dr. Vivien Béziat, Researcher at the Laboratory of Human Genetics of Infectious Diseases, and Dr. Christian Ganoza, Senior Scientist at CENTOGENE, are project leads for this collaboration.

About Institut Imagine

Located on the campus of the Necker-Enfants malades hospital, the Institut Imagine is a world leader in research, care and teaching on genetic diseases. Its unique architecture, designed by Jean Nouvel and Bernard Valéro, brings together 1,000 researchers, physicians, teacher-researchers, engineers and health care personnel in a single location to work with patients, with the ambition of accelerating research and diagnosis and therapeutic innovation to change the lives of families affected by genetic diseases. The Institut Imagine has been certified “Institut hospitalo universitaire” (IHU), in 2011 and 2019 and a “Institut Carnot”, in 2020. It is supported by six founding members, including AP-HP, Inserm and Université Paris Cité, as well as by private partners and patrons. Every day in France, 64 babies are born with a genetic disease. Nearly 8,000 genetic diseases affect more than 3 million people, of which nearly one in two is undiagnosed and more than 8 in 10 have no dedicated treatment. Faced with this public health emergency, the challenge is twofold: to diagnose and to cure.

www.institutimagine.org

About CENTOGENE

CENTOGENE’s mission is to provide data-driven, life-changing answers to patients, physicians, and pharma companies for rare and neurodegenerative diseases. We integrate multiomic technologies with the CENTOGENE Biodatabank – providing dimensional analysis to guide the next generation of precision medicine. Our unique approach enables rapid and reliable diagnosis for patients, supports a more precise physician understanding of disease states, and accelerates and de-risks targeted pharma drug discovery, development, and commercialization.

Since our founding in 2006, CENTOGENE has been offering rapid and reliable diagnosis – building a network of approximately 30,000 active physicians. Our ISO, CAP, and CLIA certified multiomic reference laboratories in Germany utilize Phenomic, Genomic, Transcriptomic, Epigenomic, Proteomic, and Metabolomic datasets. This data is captured in our CENTOGENE Biodatabank, with over 800,000 patients represented from over 120 highly diverse countries, over 70% of whom are of non-European descent. To date, the CENTOGENE Biodatabank has contributed to generating novel insights for more than 285 peer-reviewed publications.

By translating our data and expertise into tangible insights, we have supported over 50 collaborations with pharma partners. Together, we accelerate and de-risk drug discovery, development, and commercialization in target and drug screening, clinical development, market access and expansion, as well as offering CENTOGENE Biodata Licenses and Insight Reports to enable a world healed of all rare and neurodegenerative diseases.

To discover more about our products, pipeline, and patient-driven purpose, visit www.centogene.com and follow us on LinkedIn.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the U.S. federal securities laws. Statements contained herein that are not clearly historical in nature are forward-looking, and the words “anticipate,” “believe,” “continues,” “expect,” “estimate,” “intend,” “project,” “plan,” “is designed to,” “is set to,” “potential,” “predict,” “objective” and similar expressions and future or conditional verbs such as “will,” “would,” “should,” “could,” “might,” “can,” and “may,” or the negative of these are generally intended to identify forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause CENTOGENE’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, negative economic and geopolitical conditions and instability and volatility in the worldwide financial markets, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in our industry, the expense and uncertainty of regulatory approval, including from the U.S. Food and Drug Administration, changes in our mix of customers and partners and their order practices with respect to our products and solutions, our reliance on third parties and collaboration partners, including our ability to manage growth, execute our business strategy and enter into new client relationships, our dependency on the rare disease industry, our ability to manage international expansion, our reliance on key personnel, our reliance on intellectual property protection, fluctuations of our operating results due to the effect of exchange rates, our ability to streamline cash usage, our continued ongoing compliance with covenants linked to financial instruments, our requirement for additional financing, and our ability to continue as a going concern, or other factors. For further information on the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to CENTOGENE’s business in general, see CENTOGENE’s risk factors set forth in CENTOGENE’s Form 20-F filed on May 16, 2023, with the Securities and Exchange Commission (the “SEC”) and subsequent filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and CENTOGENE specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.

CONTACT

CENTOGENE

Melissa Hall
Corporate Communications
Press@centogene.com 

Lennart Streibel
Investor Relations
IR@centogene.com 

Institut Imagine

Juliette Arcos Desloges
Havas Red Health
juliette.desloges@havas.com
+33 06 07 38 35 35

Pablo Alvarez
Havas Red Health
pablo.alvarez@havas.com
+33 07 89 45 79 08

Anne Lenoir
Institut Imagine
anne.lenoir@institutimagine.org
+33 01 42 75 47 22

Marie de Bazelaire
Institut Imagine
marie.de-bazelaire@institutimagine.org 


FAQ

What is the strategic research collaboration announced by CENTOGENE N.V. (CNTG)?

CENTOGENE N.V. (CNTG) announced a strategic research collaboration with the Laboratory of Human Genetics of Infectious Diseases at Institut Imagine to accelerate and de-risk drug discovery and clinical development for rare disease patients.

What is the CENTOGENE Biodatabank and how does it contribute to the collaboration?

The CENTOGENE Biodatabank contains over 70 million unique genetic variants collected from more than 800,000 patients from over 120 countries, providing valuable insights into the role that specific genes play in disease. It will be leveraged to discover and validate novel genetic and biochemical targets for future development of rare disease therapies.

Who are the project leads for the collaboration between CENTOGENE N.V. (CNTG) and the Laboratory of Human Genetics of Infectious Diseases?

Dr. Vivien Béziat and Dr. Christian Ganoza are the project leads for this collaboration.

What is the mission of the Laboratory of Human Genetics of Infectious Diseases?

The mission is to gain a better understanding of the human genetic and immunological determinants of rare and common infectious diseases.

How many rare diseases are currently without an available treatment?

Approximately 95% of the over 7,000 rare diseases are without an available treatment.

Centogene N.V. Common Shares

NASDAQ:CNTG

CNTG Rankings

CNTG Latest News

CNTG Stock Data

9.43M
29.00M
4.57%
66.89%
0.28%
Diagnostics & Research
Healthcare
Link
United States of America
Rostock